Hypersensitivity reactions to Patent Blue v in breast cancer surgery: A prospective multicentre study

Acta Anaesthesiologica Scandinavica

Volumn 57, Issue 1, 2013, Pages 106-111

  Brenet, O ^a   Lalourcey, L ^b   Queinnec, M ^c   Dupoiron, D ^a   Jayr, C ^d   Rosay, H ^e   Mavoungou, P ^f   Monnin, D ^g   Ancel, B ^h   Maget, B ⁱ   Louvier, N ^j   Malinovsky, J A ^k  

^a Cancer Center of Angers   (France)

^b Cancer Center of Montpellier   (France)

^c Cancer Center of Paris   (France)

^d Cancer Center of Saint Cloud   (France)

^e CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^f Department of Radiation Therapy   (France)

^g University Center Hospital of Bordeaux   (France)

^h Research Center of Nancy   (France)

ⁱ Cancer Center of Reims   (France)

^j Cancer Center Dijon   (France)

^k REIMS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BETAMETHASONE; DISULFINE BLUE; EPHEDRINE; HISTAMINE; HYDROCORTISONE; LATEX; METHYLPREDNISOLONE; NEUROMUSCULAR BLOCKING AGENT; TRYPTASE;

ADULT; ALLERGIC REACTION; ARTICLE; ARTIFICIAL VENTILATION; ATOPY; BLOOD SAMPLING; BREAST CANCER; BREAST SURGERY; CANCER SURGERY; DISEASE DURATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; ERYTHEMA; HISTAMINE BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; INTRACUTANEOUS TEST; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MULTICENTER STUDY; PRICK TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE; SHOCK; SKIN TEST; URTICARIA;

AGED; ANESTHESIA, GENERAL; BREAST NEOPLASMS; COLORING AGENTS; DRUG HYPERSENSITIVITY; FEMALE; FRANCE; HISTAMINE; HUMANS; INTRAOPERATIVE COMPLICATIONS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; ROSANILINE DYES; SENTINEL LYMPH NODE BIOPSY; SKIN TESTS; TREATMENT OUTCOME; TRYPTASES;

EID: 84870974634     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12003     Document Type: Article

References (31)

1. Goyal A, Newcombe RG, Chhabra A, Mansel RE,. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer - results of the ALMANAC validation phase. Breast Cancer Res Treat 2006; 99: 203 - 208.
2. Leong SP, Donegan E, Heffernon W, Dean S, Katz JA,. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol 2000; 7: 361 - 366.
3. Cimmino VM, Brown AC, Szocik JF, Pass HA, Moline S, De SK, Domino EF,. Allergic reactions to isosulfan blue during sentinel node biopsy - a common event. Surgery 2001; 130: 439 - 442.
4. Dewachter P, Mouton-Faivre C, Benhaijoub A, Abel-Decollogne F, Mertes PM,. Anaphylactic reaction to Patent Blue V after sentinel lymph node biopsy. Acta Anaesthesiol Scand 2006; 50: 245 - 247.
5. Jeudy G, Louvier N, Rapennes T, Goujon E, Fraisse J, Dalac-Rat S, etal. Immediate patent blue-induced hypersensitivity during sentinel node detection: the value of cutaneous tests. Ann Dermatol Venereol 2008; 135: 461 - 465.
6. Wohrl S, Focke M, Hinterhuber G, Stingl G, Binder M,. Near-fatal anaphylaxis to Patent Blue V. Br J Dermatol 2004; 150: 1037 - 1038.
7. Scherer K, Bircher AJ, Figueiredo V,. Blue dyes in medicine - a confusing terminology. Contact Dermatitis 2006; 54: 231 - 232.
8. Scherer K, Studer W, Figueiredo V, Bircher AJ,. Anaphylaxis to isosulfan blue and cross-reactivity to Patent Blue V: case report and review of the nomenclature of vital blue dyes. Ann Allergy Asthma Immunol 2006; 96: 497 - 500.
9. Raut CP, Hunt KK, Akins JS, Daley MD, Ross MI, Singletary SE, etal. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer 2005; 104: 692 - 699.
10. Montgomery LL, Thorne AC, Van Zee KJ, Fey J, Heerdt AS, Gemignani M, etal. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg 2002; 95: 385 - 388.
11. Albo D, Wayne JD, Hunt KK, Rahlfs TF, Singletary SE, Ames FC, etal. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg 2001; 182: 393 - 398.
12. King TA, Fey JV, Van Zee KJ, Heerdt AS, Gemignani ML, Port ER, etal. A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer. Ann Surg Oncol 2004; 11: 535 - 541.
13. Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, etal. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006; 13: 491 - 500.
14. White V, Harvey JR, Griffith CD, Youssef M, Carr M,. Sentinel lymph node biopsy in early breast cancer surgery - working with the risks of vital blue dye to reap the benefits. Eur J Surg Oncol 2011; 37: 101 - 108.
15. Beenen E, de Roy van Zuidewijn DB,. Patients blue on patent blue: an adverse reaction during four sentinel node procedures. Surg Oncol 2005; 14: 151 - 154.
16. Barthelmes L, Goyal A, Newcombe RG, McNeill F, Mansel RE,. Adverse reactions to Patent Blue V dye - The NEW START and ALMANAC experience. Eur J Surg Oncol 2010; 36: 399 - 403.
17. Gill G,. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 2009; 16: 266 - 275.
18. Rodier JF, Velten M, Wilt M, Martel P, Ferron G, Vaini-Elies V, etal. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol 2007; 25: 3664 - 3669.
19. Hunting AS, Nopp A, Johansson SG, Andersen F, Wilhelmsen V, Guttormsen AB,. Anaphylaxis to Patent Blue V. I. Clinical aspects. Allergy 2010; 65: 117 - 123.
20. Malinovsky JM, Decagny S, Wessel F, Guilloux L, Mertes PM,. Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients. Acta Anaesthesiol Scand 2008; 52: 175 - 181.
21. Ring J, Messmer K,. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1: 466 - 469.
22. Société francaise d'anesthésie et réanimation, Société francaise d'allergologie. Prevention du risque allergique peranesthesique. Texte court. Ann Fr Anesth Reanim 2011; 30: 212 - 222.
23. Harboe T, Guttormsen AB, Irgens A, Dybendal T, Florvaag E,. Anaphylaxis during anesthesia in Norway: a 6-year single-center follow-up study. Anesthesiology 2005; 102: 897 - 903.
24. Dewachter P, Mouton-Faivre C, Emala CW,. Anaphylaxis and anesthesia: controversies and new insights. Anesthesiology 2009; 111: 1141 - 1150.
25. Mertes PM, Malinovsky JM, Mouton-Faivre C, Bonnet-Boyer MC, Benhaijoub A, Lavaud F, etal. Anaphylaxis to dyes during the perioperative period: reports of 14 clinical cases. J Allergy Clin Immunol 2008; 122: 348 - 352.
26. Lanitis S, Filippakis G, Sidhu V, Al Mufti R, Lee TH, Hadjiminas DJ,. Atypical anaphylactic reaction to Patent Blue during sentinel lymph node biopsy for breast cancer. Ann R Coll Surg Engl 2008; 90: 338 - 339.
27. Thierrin L, Steiger D, Zuber JP, Spertini F, Brunisholz Y, Delaloye JF,. Severe anaphylactic shock to Patent Blue V with cardiac arrest during breast carcinoma surgery with lymphatic mapping. Eur J Obstet Gynecol Reprod Biol 2008; 140: 140 - 141.
28. Barthelmes L, Goyal A, Sudheer P, Mansel RE,. Investigation of anaphylactic reaction after Patent Blue V dye injection. Breast 2010; 19: 516 - 520.
29. Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM,. Catecholamine-induced cardiomyopathy. Endocr Pract 2008; 14: 1137 - 1149.
30. Johansson SG, Nopp A, Oman H, Stahl-Skov P, Hunting AS, Guttormsen AB,. Anaphylaxis to Patent Blue V. II. A unique IgE-mediated reaction. Allergy 2010; 65: 124 - 129.
31. Mertes PM, Laxenaire MC, Alla F,. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 2003; 99: 536 - 545.